{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:30:10Z","timestamp":1794097810028,"version":"4.8.0"},"reference-count":70,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2023,9,19]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>Euglycemic diabetic ketoacidosis (EDKA) is an emerging complication of diabetes associated with an increasing use of sodium-glucose transporter type 2 (SGLT-2) inhibitor drugs. This review highlights the growing incidence of EDKA and its diagnostic challenges due to the absence of hallmark hyperglycemia seen in diabetic ketoacidosis (DKA). The paper presents a classification system for the severity of EDKA, categorizing it into mild, moderate, and severe based on serum pH and bicarbonate levels. Another classification system is proposed to define stages of EDKA based on anion gap and ketones at the time of diagnosis and during the treatment period. A treatment algorithm is proposed to guide clinicians in managing EDKA. This treatment algorithm includes monitoring anion gap and ketones to guide insulin and fluid management, and slower transition to subcutaneous insulin to prevent a relapse. Increased awareness of EDKA is essential for a timely diagnosis because an early diagnosis and treatment can improve clinical outcomes.<\/jats:p>","DOI":"10.1136\/bmjdrc-2023-003666","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T23:20:33Z","timestamp":1696461633000},"page":"e003666","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":166,"title":["Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors"],"prefix":"10.1136","volume":"11","author":[{"given":"Erica","family":"Chow","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Harbor-UCLA Medical Center, Torrance, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Clement","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Inova Fairfax Hospital, Falls Church, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7779-1619","authenticated-orcid":false,"given":"Rajesh","family":"Garg","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Harbor-UCLA Medical Center, Torrance, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"2025073113084543000_11.5.e003666.1","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s11845-021-02761-6","article-title":"Sodium glucose co-transporter-2 inhibitor, empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1C levels in type 2 diabetic patients with established coronary heart disease: the SUPER GATE study","volume":"191","author":"Bilgin","year":"2022","journal-title":"Ir J Med Sci"},{"key":"2025073113084543000_11.5.e003666.2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/17446651.2023.2204941","article-title":"Treatment of type 2 diabetes patients with heart conditions","volume":"18","author":"Aktas","year":"2023","journal-title":"Expert Review of Endocrinology & Metabolism"},{"key":"2025073113084543000_11.5.e003666.3","unstructured":"European Medicines Agency . Review of diabetes medicines called Sglt2 inhibitors started: risk of diabetic ketoacidosis to be examined. 2015. Available: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/sglt2-inhibitors-article-20-procedure-review-started_en.pdf [Accessed 31 Jul 2023]."},{"key":"2025073113084543000_11.5.e003666.4","unstructured":"Health Canada. Forxiga, Invokana . Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosis. Ottawa, ON: Health Canada, 2015. Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/safety-reviews\/summary-safety-review-sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin.html"},{"key":"2025073113084543000_11.5.e003666.5","unstructured":"US Food Drug Administration . FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Drug safety communications. 2015. Available: https:\/\/wwwfdagov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious#:~:text=%5B12%2D4%2D2015%5D,of%20serious%20urinary%20tract%20infections"},{"key":"2025073113084543000_11.5.e003666.6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.29271\/jcpsp.2022.07.928","article-title":"A case of euglycemic diabetic ketoacidosis due to empagliflozin use in a patient with type 1 diabetes mellitus","volume":"32","author":"Bilgin","year":"2022","journal-title":"J Coll Physicians Surg Pak"},{"key":"2025073113084543000_11.5.e003666.7","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-9916"},{"key":"2025073113084543000_11.5.e003666.8","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.jcjd.2017.10.013","article-title":"Hyperglycemic emergencies in adults","volume":"42 Suppl 1","author":"Goguen","year":"2018","journal-title":"Can J Diabetes"},{"key":"2025073113084543000_11.5.e003666.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5866.578"},{"key":"2025073113084543000_11.5.e003666.10","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7074868","article-title":"Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis","volume":"2018","author":"Yu","year":"2018","journal-title":"Int J Endocrinol"},{"key":"2025073113084543000_11.5.e003666.11","doi-asserted-by":"publisher","DOI":"10.1007\/BF00569937"},{"key":"2025073113084543000_11.5.e003666.12","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ajhp\/zxac056","article-title":"Time-series analysis of recent antihyperglycemic medication prescribing trends for a diverse sample of medicare enrollees with type 2 diabetes mellitus in an integrated health system","volume":"79","author":"Miller","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"2025073113084543000_11.5.e003666.13","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/dom.14408","article-title":"Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019","volume":"23","author":"Heyward","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025073113084543000_11.5.e003666.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"2025073113084543000_11.5.e003666.15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023811","article-title":"National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025073113084543000_11.5.e003666.16","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.936651","article-title":"Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: an infodemiological study","volume":"9","author":"Dzaye","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025073113084543000_11.5.e003666.17","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1943"},{"key":"2025073113084543000_11.5.e003666.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2025073113084543000_11.5.e003666.19","unstructured":"Food U , Administration D . FDA warns that Sglt2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. In: Drug safety communications[homepage en internet]. 2015."},{"key":"2025073113084543000_11.5.e003666.20","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0289"},{"key":"2025073113084543000_11.5.e003666.21","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1730"},{"key":"2025073113084543000_11.5.e003666.22","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2806"},{"key":"2025073113084543000_11.5.e003666.23","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1087"},{"key":"2025073113084543000_11.5.e003666.24","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther"},{"key":"2025073113084543000_11.5.e003666.25","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843"},{"key":"2025073113084543000_11.5.e003666.26","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1251"},{"key":"2025073113084543000_11.5.e003666.27","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1749"},{"key":"2025073113084543000_11.5.e003666.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.04.004"},{"key":"2025073113084543000_11.5.e003666.29","doi-asserted-by":"crossref","unstructured":"Blau JE , Tella SH , Taylor SI , et al . Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev 2017;33. doi:10.1002\/dmrr.2924","DOI":"10.1002\/dmrr.2924"},{"key":"2025073113084543000_11.5.e003666.30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dom.13012","article-title":"Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature","volume":"20","author":"Bonora","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025073113084543000_11.5.e003666.31","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160421121307"},{"key":"2025073113084543000_11.5.e003666.32","article-title":"Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma","volume":"2017","author":"Rawla","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2025073113084543000_11.5.e003666.33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11606-008-0829-0","article-title":"Starvation-induced true diabetic euglycemic ketoacidosis in severe depression","volume":"24","author":"Joseph","year":"2009","journal-title":"J Gen Intern Med"},{"key":"2025073113084543000_11.5.e003666.34","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2001.20194"},{"key":"2025073113084543000_11.5.e003666.35","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00592-022-01909-9","article-title":"Sglt2-inhibitors and Euglycemic diabetic Ketoacidosis in COVID-19 pandemic era: a case report","volume":"59","author":"Secinaro","year":"2022","journal-title":"Acta Diabetol"},{"key":"2025073113084543000_11.5.e003666.36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884"},{"key":"2025073113084543000_11.5.e003666.37","article-title":"Euglycemic diabetic ketoacidosis and sodium-glucose cotransporter-2 inhibitors: a focused review of pathophysiology, risk factors, and triggers","volume":"13","author":"Somagutta","year":"2021","journal-title":"Cureus"},{"key":"2025073113084543000_11.5.e003666.38","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1881"},{"key":"2025073113084543000_11.5.e003666.39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2025073113084543000_11.5.e003666.40","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.3109\/14767058.2015.1107903","article-title":"Ketoacidosis in diabetic pregnancy","volume":"29","author":"Dalfr\u00e0","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2025073113084543000_11.5.e003666.41","first-page":"590","article-title":"Euglycemic diabetic ketoacidosis in pregnancy","volume":"18","author":"Tarif","year":"2007","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2025073113084543000_11.5.e003666.42","article-title":"Euglycemic diabetic ketoacidosis in pregnancy: a case report and review of current literature","volume":"2019","author":"Jaber","year":"2019","journal-title":"Case Rep Crit Care"},{"key":"2025073113084543000_11.5.e003666.43","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000060"},{"key":"2025073113084543000_11.5.e003666.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2007.08.001"},{"key":"2025073113084543000_11.5.e003666.45","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.3.5871.107-a","article-title":"Euglycemic diabetic ketoacidosis","volume":"3","author":"Ireland","year":"1973","journal-title":"Br Med J"},{"key":"2025073113084543000_11.5.e003666.46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70704"},{"key":"2025073113084543000_11.5.e003666.47","doi-asserted-by":"publisher","DOI":"10.2337\/diab.32.5.387"},{"key":"2025073113084543000_11.5.e003666.48","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3828"},{"key":"2025073113084543000_11.5.e003666.49","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2337\/dc22-0885","article-title":"Distinct mechanisms responsible for the increase in glucose production and ketone formation caused by empagliflozin in T2Dm patients","volume":"46","author":"Abdelgani","year":"2023","journal-title":"Diabetes Care"},{"key":"2025073113084543000_11.5.e003666.50","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12330"},{"key":"2025073113084543000_11.5.e003666.51","article-title":"Euglycemic diabetic ketoacidosis in the ICU: 3 case reports and review of literature","volume":"2018","author":"Lucero","year":"2018","journal-title":"Case Rep Crit Care"},{"key":"2025073113084543000_11.5.e003666.52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ccr3.3540","article-title":"Euglycemic DKA (euDKA) as a presentation of COVID-19","volume":"9","author":"Dass","year":"2021","journal-title":"Clin Case Rep"},{"key":"2025073113084543000_11.5.e003666.53","article-title":"Euglycemic diabetic ketoacidosis in a patient with cocaine intoxication","volume":"2016","author":"Abu-Abed Abdin","year":"2016","journal-title":"Case Rep Crit Care"},{"key":"2025073113084543000_11.5.e003666.54","first-page":"62","article-title":"Euglycemic diabetic ketoacidosis due to gastroparesis, a local experience","volume":"112","author":"Legaspi","year":"2015","journal-title":"J Ark Med Soc"},{"key":"2025073113084543000_11.5.e003666.55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/1947-2714.157490","article-title":"Euglycemic diabetic ketoacidosis, a misleading presentation of diabetic ketoacidosis","volume":"7","author":"Thawabi","year":"2015","journal-title":"North Am J Med Sci"},{"key":"2025073113084543000_11.5.e003666.56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11695-018-3548-6","article-title":"Normal blood glucose and high blood ketones in a critically unwell patient with T1Dm post-bariatric surgery: a case of euglycemic diabetic ketoacidosis","volume":"29","author":"Dowsett","year":"2019","journal-title":"Obes Surg"},{"key":"2025073113084543000_11.5.e003666.57","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s11695-015-1999-6","article-title":"Type 1 diabetes mellitus and bariatric surgery: a systematic review and meta-analysis","volume":"26","author":"Ashrafian","year":"2016","journal-title":"Obes Surg"},{"key":"2025073113084543000_11.5.e003666.58","article-title":"Euglycemic diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitor use post-bariatric surgery: a brief review of the literature","volume":"12","author":"Iqbal","year":"2020","journal-title":"Cureus"},{"key":"2025073113084543000_11.5.e003666.59","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5680","article-title":"Euglycemic diabetic ketoacidosis in pregnancy with COVID-19: a case report and literature review","volume":"10","author":"Wazir","year":"2022","journal-title":"Clin Case Rep"},{"key":"2025073113084543000_11.5.e003666.60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2008.00720.x"},{"key":"2025073113084543000_11.5.e003666.61","first-page":"452","article-title":"Diabetic ketoacidosis occurring with lower blood glucose levels in pregnancy: a report of two cases","volume":"57","author":"Madaan","year":"2012","journal-title":"J Reprod Med"},{"key":"2025073113084543000_11.5.e003666.62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1991.tb01616.x"},{"key":"2025073113084543000_11.5.e003666.63","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2001.00558.x"},{"key":"2025073113084543000_11.5.e003666.64","article-title":"Starvation ketoacidosis: a cause of severe anion gap metabolic acidosis in pregnancy","volume":"2014","author":"Sinha","year":"2014","journal-title":"Case Rep Crit Care"},{"key":"2025073113084543000_11.5.e003666.65","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0140-6736(82)91750-0","article-title":"Accelerated starvation\" and the skipped breakfast in late normal pregnancy","volume":"1","author":"Metzger","year":"1982","journal-title":"Lancet"},{"key":"2025073113084543000_11.5.e003666.66","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4158\/EP161447.LT","article-title":"Diabetic ketoacidosis in patients with type 2 diabetes recently commenced on SGLT-2 inhibitors: an ongoing concern","volume":"23","author":"Ahmed","year":"2017","journal-title":"Endocr Pract"},{"key":"2025073113084543000_11.5.e003666.67","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380"},{"key":"2025073113084543000_11.5.e003666.68","doi-asserted-by":"publisher","DOI":"10.1136\/emj.2004.017590"},{"key":"2025073113084543000_11.5.e003666.69","doi-asserted-by":"publisher","DOI":"10.1053\/jcrc.2000.7900"},{"key":"2025073113084543000_11.5.e003666.70","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: a missed diagnosis","volume":"12","author":"Nasa","year":"2021","journal-title":"World J Diabetes"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2023-003666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:08:59Z","timestamp":1753992539000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2023-003666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":70,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,10,4]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bmjdrc-2023-003666"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2023-003666","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}